Survival Benefit From Immunotherapy With Modified Poliovirus in Recurrent Glioblastoma?

A noncontrolled phase I study in recurrent metastatic glioblastoma showed 3-year survival was five times higher in patients treated with intratumoral PVSRIPO.

Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news